# Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT00006942** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 32 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Primary Peritoneal Cavity Cancer
- Recurrent Ovarian Epithelial Cancer
- Stage III Ovarian Epithelial Cancer
- Stage IV Ovarian Epithelial Cancer

## Interventions

- **DRUG:** bryostatin 1
- **DRUG:** cisplatin
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00006942
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10
- **Primary completion:** 2004-03
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006942, "Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00006942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*